---
title: "Sarepta 報告其基因療法出現第二例死亡病例"
description: "Sarepta Therapeutics 公司報告其基因療法出現第二例死亡病例，一名接受 Elevidys 治療的患者因急性肝衰竭去世。三個月前，另一名十幾歲男孩也因相同治療死亡。兩例均為杜氏肌營養不良症且無法行走的患者。公司已暫停相關臨牀試驗，並停止向此類患者提供該藥物，正在考慮加強免疫抑制方案。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/244583352.md"
published_at: "2025-06-15T13:56:21.000Z"
---

# Sarepta 報告其基因療法出現第二例死亡病例

> Sarepta Therapeutics 公司報告其基因療法出現第二例死亡病例，一名接受 Elevidys 治療的患者因急性肝衰竭去世。三個月前，另一名十幾歲男孩也因相同治療死亡。兩例均為杜氏肌營養不良症且無法行走的患者。公司已暫停相關臨牀試驗，並停止向此類患者提供該藥物，正在考慮加強免疫抑制方案。

Sarepta Therapeutics 公司稱，又有一名接受其罕見肌肉疾病基因療法治療的患者因急性肝衰竭死亡。該公司表示，這起死亡事件發生在一名接受一次性治療藥物 Elevidys 的患者身上，而三個月前，一名十幾歲男孩在接受該治療後死亡。兩起病例均發生在患有杜氏肌營養不良症且無法行走的患者身上。該公司已暫停一項臨牀試驗，停止向無法行走的患者運送該藥物，並正在考慮為這些患者加強免疫抑制方案。

### Related Stocks

- [SRPT.US - Sarepta醫療](https://longbridge.com/zh-HK/quote/SRPT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Sarepta rises on NZ regulatory nod to start Huntington's disease trial | Sarepta Therapeuticsshares rose 3% to $20.92 in premarket trading after receiving regulatory approval in New Zealand to  | [Link](https://longbridge.com/zh-HK/news/274824082.md) |
| Forecasting The Future: 8 Analyst Projections For Sarepta Therapeutics | During the last three months, 8 analysts evaluated Sarepta Therapeutics (NASDAQ:SRPT), showing a range of bullish to bea | [Link](https://longbridge.com/zh-HK/news/272548848.md) |
| Tempered Growth Outlook and Heightened Regulatory Risk Drive Sell Rating on Sarepta Therapeutics | Needham analyst Gil Blum has reiterated a Sell rating on Sarepta Therapeutics (SRPT) due to concerns over its growth out | [Link](https://longbridge.com/zh-HK/news/272438221.md) |
| Sarepta Therapeutic Q4 prelim net product revenue misses estimates | Sarepta Therapeutics reported preliminary Q4 net product revenue of $369.6 million, missing analyst estimates of $382.07 | [Link](https://longbridge.com/zh-HK/news/272301526.md) |
| JPM26: Sarepta CEO touts “avalanche of Elevidys data” amid 2025 safety woes | Sarepta's CEO Douglas Ingram presented at the J.P. Morgan Healthcare Conference, discussing the challenges faced by Elev | [Link](https://longbridge.com/zh-HK/news/272413649.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。